Davis’s Drug Guide for Nurses is a medical reference tool by Skyscape Medpresso Inc that provides comprehensive drug monographs for nursing professionals. The app claims to support safe medication administration through integrated dosing calculators and cross-referenced drug data.
Overview · Full Intel report in progress
The App DNA
What makes this app unique?
For Nursing students and practicing healthcare professionals.
Key features
Provides access to over 1,400 monographs covering 5,000 trade and generic drugs.
Includes over 700 built-in tools to calculate dosages directly within the drug monograph.
Offers audio support for approximately 890 generic drug names.
Delivers ongoing news and updates regarding FDA drug information.
How much does it cost?
Velocity
Active developmentShow more...
5 versions in history. Development pace: active.
Who built it?
Skyscape Medpresso
13+ apps tracked · Medical
User Sentiment
What do users think recently?
How are ratings & reviews evolving?
Not enough recent reviews to extract reliable themes yet.
Read the full review analysisCompetition
Competitive landscape for Davis’s Drug Guide for Nurses
How's the Medical market?
The rivals identified
By Epocrates
Both apps target healthcare professionals with clinical drug reference tools, creating direct competition for daily clinical decision support.
- Epocrates includes a visual pill identification tool, while Davis’s Drug Guide for Nurses lacks this visual lookup capability.
- Epocrates provides full offline database functionality, allowing access to clinical data without an active network connection.
- Epocrates features a 30-drug interaction checker, a specialized clinical tool not listed in the Davis’s Drug Guide feature set.
Unlock the head-to-head verdict: where this rival wins, and where it loses.
Access the full report for freeThe Analyst's Read
Key takeaways for Davis’s Drug Guide for Nurses
Where is it heading?
Bottom line
While the app offers extensive clinical reference data and integrated calculators, users report significant technical issues regarding subscription management and text accessibility.
Report last updated